The market for GLP-1 (glucagon-like peptide-1) receptor agonists is quickly becoming a profitable investment option. Despite these medications' promising efficacy and expanding indications, the market faces significant challenges that need innovative solutions. Dr. Jonathan Kaplan, a renowned plastic surgeon and entrepreneur, has strategically positioned his company, BuildMyHealth, to tackle these obstacles and take advantage of the vast opportunities in the GLP-1 market. The company also aims to help physicians, typically dependent on insurance reimbursement, thrive with a cash payment model.
The High Demand and Supply Shortage Dilemma
GLP-1 receptor agonists were first created to help people with type 2 diabetes, but now they have become increasingly popular due to their ability to promote weight loss. The FDA's authorization for using these drugs to address obesity has created a large market. In the U.S., 42% of adults are classified as obese, creating a potential customer base of 138 million individuals. Furthermore, there is expected to be a global increase in demand for these medications with recent approvals in high-obesity countries like China.
However, this burgeoning demand has resulted in significant supply deficits. Leading pharmaceutical companies are facing challenges to keep up as their production facilities are unable to meet the necessary output. To illustrate, if only the obese population in the United States were to be catered to, it would require 7.2 billion injections for the once-per-week shots over the course of a year. However, the current manufacturing capacity falls significantly below this number, and experts in the industry predict that it will take several years to close this gap.
The Role of Compounding Pharmacies
Compounding pharmacies have stepped in to address the scarcity of well-known GLP-1 drugs. They have the legal authority to manufacture the active ingredients found in these drugs, offering a more affordable and easily accessible alternative. This is particularly significant given the uncertainty of insurance coverage for these treatments, as certain plans may not cover them or impose stringent restrictions.
People who don't have insurance or have to pay $1000+ per month for the name brand medications, can use compounding pharmacies. But there are challenges with this option. To get the medicines they need, patients often use direct-to-consumer (DTC) websites. Unfortunately, these websites lack the proper medical supervision needed to address potential side effects like nausea, vomiting, and diarrhea. This underscores the need for a more complete approach where patients can get ongoing care from a dedicated provider while they achieve their weight loss goals.
Dr. Jonathan Kaplan's Solution with BuildMyHealth
Dr. Jonathan Kaplan, leveraging his expertise as a plastic surgeon, saw the opportunities and challenges in the GLP-1 market. He created BuildMyHealth, a platform that connects patients and providers for better care. BuildMyHealth lets patients get GLP-1 medications from compounding pharmacies and receive ongoing support from their healthcare providers.
This model addresses a critical need: continuity of care. Instead of patients depending on impersonal Direct-to-Consumer (DTC) websites, BuildMyHealth connects them with providers, or, as they like to call it, provider-to-consumer (PTC) connections. These providers can oversee their progress, handle side effects, and provide comprehensive healthcare solutions. This results in better outcomes for patients and an improved overall experience, which leads to trust and compliance with treatment plans.
The Provider Opportunity
Healthcare providers have a great opportunity with the increasing trend towards cash-based revenue models. In the past, specialties like plastic surgery and aesthetic medicine were the main ones that relied on cash payments. However, now, the GLP-1 market allows various providers, including gastroenterologists, primary care providers, orthopedic surgeons, dermatologists, cardiologists, bariatric surgeons, and many others, to offer cash-pay services. This shift is appealing because it reduces reliance on insurance reimbursements, which can often be slow, bureaucratic, or completely interrupted, as seen in the recent Change Healthcare cyberattack.
Now, healthcare providers have the opportunity to adopt a subscription-based approach, offering these medications and ensuring continuity of care. This not only enhances the results for patients but also ensures a stable income for the providers. The uses for GLP-1 drugs are expanding, covering a wide range of conditions that have already received FDA approval, such as heart disease but also future indications like fatty liver, sleep apnea, chronic kidney disease, and alcohol use disorder. This broadens the potential patient population that can benefit from these medications. In the end, nearly all Americans could gain advantages from these medications, either directly or indirectly, considering the widespread prevalence of conditions like obesity and its related comorbidities.
The Broader Market Dynamics
The GLP-1 market has huge potential from an economic perspective. These medications are effective and safe, making them attractive for many patients. Pharmaceutical companies are investing billions to expand production, but it will take a long time to meet the demand. This creates an opportunity for new solutions, whether through new production technologies, alternative distribution models, or integrated care platforms.
In addition, as society changes, the stigma of using weight loss medications for non-medical reasons is likely to decrease, similar to the trajectory seen with cosmetic procedures like Botox. This cultural shift will increase the demand for GLP-1 medications, making it an even more appealing investment.
Conclusion
BuildMyHealth, developed by Dr. Jonathan Kaplan, is well-positioned to navigate the complexities of the GLP-1 market, helping both patients and providers to succeed. By offering a comprehensive solution that addresses the high demand and supply shortages, BuildMyHealth benefits patients and providers. This not only improves patient care but also taps into the economic potential of the GLP-1 market, making it an attractive opportunity for venture capital investment. As healthcare continues to evolve, innovative companies like BuildMyHealth will be at the forefront of transforming patient outcomes and driving industry growth.
Join the Conversation